Antibodies to CD23, derivatives thereof, and their therapeutic uses
US7008623B1 · kind B1 · utility
6Cited by
2References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 1999 |
| Grant date | Mar 7, 2006 |
| Priority date | — |
| Expiry date | May 7, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to antibodies which bind to the CD23 (FCεRII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FCεRII) type II molecule characterized by an affinity constant equal to or greater than 1×109 Ka Mol−1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.